Abstract
Prostate cancer is an increasingly prevalent health problem among males, and the need for improved methods of treatment is great. In the 1940s estrogens were shown to be of benefit in prostate cancer, and their use continued for some 30 years, until the advent of LHRH agonists and similar drugs. At the time the mechanism of action of estrogens was thought to involve merely reduction in androgen levels, but new evidence, including expression of estrogen receptors by prostate epithelium and prostate cancer results showing a direct cytotoxic effect on prostate cancer, and preclinical data on inhibition of prostate cancer in intact female mice, suggests that estrogen exerts other effects on prostate cancer cells. Given that estrogens also decrease bone lysis caused by androgen suppression and may ameliorate cognitive side effects associated with low testosterone, estrogens show promise in treatment of androgen-independent prostate cancer. This review summarizes published reports of the effects on estrogens on prostate cancer in preclinical and clinical settings.
Keywords: Prostate cancer, estrogen, estradiol
Current Cancer Therapy Reviews
Title: Estrogen in Prostate Cancer - Friend or Foe?
Volume: 2 Issue: 4
Author(s): Eva Corey
Affiliation:
Keywords: Prostate cancer, estrogen, estradiol
Abstract: Prostate cancer is an increasingly prevalent health problem among males, and the need for improved methods of treatment is great. In the 1940s estrogens were shown to be of benefit in prostate cancer, and their use continued for some 30 years, until the advent of LHRH agonists and similar drugs. At the time the mechanism of action of estrogens was thought to involve merely reduction in androgen levels, but new evidence, including expression of estrogen receptors by prostate epithelium and prostate cancer results showing a direct cytotoxic effect on prostate cancer, and preclinical data on inhibition of prostate cancer in intact female mice, suggests that estrogen exerts other effects on prostate cancer cells. Given that estrogens also decrease bone lysis caused by androgen suppression and may ameliorate cognitive side effects associated with low testosterone, estrogens show promise in treatment of androgen-independent prostate cancer. This review summarizes published reports of the effects on estrogens on prostate cancer in preclinical and clinical settings.
Export Options
About this article
Cite this article as:
Corey Eva, Estrogen in Prostate Cancer - Friend or Foe?, Current Cancer Therapy Reviews 2006; 2 (4) . https://dx.doi.org/10.2174/157339406778699231
DOI https://dx.doi.org/10.2174/157339406778699231 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery New Strategies and Biological Agents in the Treatment of Autoimmune Inflammatory Diseases. Progress and Challenges
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Effects of Liver Diseases on Drug-metabolizing Enzymes: Implications for Drug Fate Alterations and Nano-therapeutic Openings
Current Medicinal Chemistry Patent Selections:
Current Biomarkers (Discontinued) Importance of Pharmacology Knowledge by Dieticians
Current Nutrition & Food Science Fig Latex (Ficus carica L. cultivar Dottato) in Combination with UV Irradiation Decreases the Viability of A375 Melanoma Cells In Vitro
Anti-Cancer Agents in Medicinal Chemistry The Janus Face of CD4+CD25+ Regulatory T Cells in Cancer and Autoimmunity
Current Medicinal Chemistry Nucleophilic 18F-Fluorination of Complex Molecules in Activated Carbocyclic Aromatic Position
Current Radiopharmaceuticals Antioxidant Effects of Natural Bioactive Compounds
Current Pharmaceutical Design The Vitamin D Saga: Breaking Dawn
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Influence of Usnic Acid and its Derivatives on the Activity of Mammalian Poly(ADP-ribose)polymerase 1 and DNA Polymerase β
Medicinal Chemistry Rectal Cancer: Adjuvant Therapy and New Directions
Reviews on Recent Clinical Trials Direct Selection of cDNAs from Filamentous Phage Surface Display Libraries: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Effects of Epirubicin and Cisplatin Against 4T1 Breast Cancer Cells are Enhanced by Myrtucommulone-A
Anti-Cancer Agents in Medicinal Chemistry Classifications and Clinical Assessment of Haemorrhoids: The Proctologist’s Corner
Reviews on Recent Clinical Trials 5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly(ADP-Ribose)Polymerases (PARPs)
Current Medicinal Chemistry Preface
Current Cancer Therapy Reviews An Overview on Different Classes of Viral Entry and Respiratory Syncitial Virus (RSV) Fusion Inhibitors
Current Medicinal Chemistry Environmentally Sensitive Paramagnetic and Diamagnetic Contrast Agents for Nuclear Magnetic Resonance Imaging and Spectroscopy
Current Topics in Medicinal Chemistry